New Triple-Drug cocktail targets Hard-to-Treat bone marrow cancer

NCT ID NCT05556798

First seen Jan 07, 2026 · Last updated May 07, 2026 · Updated 16 times

Summary

This early-phase study is testing whether a combination of three drugs—belantamab mafodotin, nirogacestat, and pomalidomide—is safe for people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of belantamab when given with the other two drugs. Researchers will also check if the combination can slow or stop cancer growth. The study involves 9 participants and is currently active but no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.